What is Senisca?
SENISCA is an award-winning biotechnology firm dedicated to targeting the fundamental processes of cellular aging, known as senescence. The company's core mission involves developing RNA senotherapeutics designed to specifically address the molecular mechanisms driving senescence. By focusing on these causative factors, SENISCA aims to create innovative treatments for a spectrum of age-related conditions, positioning itself at the forefront of regenerative medicine and longevity research.
How much funding has Senisca raised?
Senisca has raised a total of $7.2M across 2 funding rounds:
Angel/Seed
$2.5M
Other Financing Round
$4.7M
Angel/Seed (2022): $2.5M with participation from Trend Ventures, Longevity Tech Fund, Emerging Longevity Ventures, and R42 Fund
Other Financing Round (2024): $4.7M led by APEX Ventures and R42 Group
Key Investors in Senisca
APEX Ventures
APEX Ventures is a venture capital firm focused on deep-tech and medical innovations, aiming to build the next generation of world-leading companies. They provide valuable guidance and resources to early-stage companies, helping them navigate commercialization and scale effectively.
R42 Group
R42 Group is a venture capital fund and institute that focuses on inventing, investing, and informing in areas such as AI, deep science, biotech, and fintech. The company actively supports deep science ventures from the pre-seed inventing stage to growth stage.
Longevity Tech Fund
Undisclosed investor participating in the funding round.
What's next for Senisca?
With this recent major strategic investment, Senisca is poised to accelerate its research and development pipeline. The substantial enterprise-level funding suggests a focus on scaling operations, potentially expanding clinical trials, and further solidifying its technological platform. This capital will likely be instrumental in advancing their RNA senotherapeutics from preclinical stages towards broader therapeutic applications, aiming to translate their scientific breakthroughs into tangible treatments for age-related diseases.
See full Senisca company page
